Thanks Mark.
the XXth, begins new presenting on therapies. our September mentioned, quite each ESMO on As we'll meeting be Mark at of year's this busy data that investigational
small on therapy designation I in based touch trilociclib briefly data, FDA press process. are the breakthrough context cell on granted lung and release, three X life-threatening is milo development the trials. want of serious expedite data Phase Breakthrough preservation conditions. where patients this from drugs announced status to or around randomized our review In intended we has regulatory we designed cancer to afternoon's in Before providing those for
received meeting submission for will next month NDA more Our been once on pre-NDA from written a update has we an minutes scheduled and the steps that definitive provide meeting. and next timeline have we
our the X FDA, discussions We the We data their regarding on and feedback looking the with forward triple-negative of with breast FDA recent findings to overall parallel are did end trial. we're also Phase discussions survival data. the survival having have these from during metastatic cancer the TNBC positive getting not
the on TNBC written from for have We that next will steps minutes once meeting. provide received update we an
our Turning on degrader to are present ESMO, or estrogen we excited GXTXX, SERD. selective first clinical receptor to data the
head estrogen tamoxifen, targeted or in estrogen receptor more shown the is inhibitors background the and blocking why treat on those approach trials, effective for oncology, been be there effective in some be aromatase as cancer. head proven SERD, best-understood oral to has the enthusiasm its most one for First, to injectable targets effective SERD. block therapies breast the widely used demonstrating than receptor and ER-mediated therapies, cancer, in ER-positive of drugs to to are The is have effects, In signaling. estrogen such field is and breast fulvestrant, that production estrogen such that an that intramuscular degrading the therapies
also CERD is for setting longer. profile meet five the be profile in and often tolerability combination order the of other However, line since Treatment injections setting, development potential an can for and would as profile fulvestrant tolerability inhibitor targeted oral Safety such and in this use improve therapy poor oral can efficacy many of are a standard or disease is setting. the adjuvant a CERD has safety This therapies, combination adjuvant adjuvant CDKXX and in have precluded the and needed its of and to fulvestrant to for important bioavailability, monthly. first A aromatase in to consideration an well-tolerated that become and used agents. has or the and the In with in exceed patients needs on the be inhibitors years existing painful for the would care setting. treatment receive advanced oral tamoxifen. CERD an
ESMO toxicities or include dose-limiting GXTXX been PK, data reported serious PAP, presented fast at being safety, There GXTXX adverse no have will to events with tolerability, efficacy. and date.
the on We X XXXX. the necessary We and oral the has have GXTXX's database of that a class completed trial in are that to CERDs to pivotal end proven issues it And, proprietary expect a of oral which development. have in is with chemistry, by in differentiates the based CERDs year, now the other the trials in in and from portion be have development. defined the profile safety the overcome and best other for drug in dose-escalation of millions dose patients GXTXX enrolling women, safety expansion. dose believe Phase tolerability challenged
and limited not presenting duration of has cancer. few trials. early to rate in are response of forward endpoints the presenting most both, population first portion the we we with will a OS treatment. or and Three, this in line having inhibitor, received and and into One, we response for stabilization and of be been the patient dose approximately will heavily approvable indicator of fulvestrant, are PFS advanced with breast the be from patients the PFS. will for taking pivotal activity pretreated, reported. There serve second patients, be rate, and points reasonable efficacy as typically either did not and meaningful data a majority Clinical surrogate in which Two, mind CDKXX the includes will is the clinical slow-growing tumor benefit be receive keep a an regarding anti-tumor prolonged dose-escalation that can data rate disease, XX data
treatment to context. of patient-level So we history showing and efficacy be in trial, data given heterogeneity will the this patients prior provide
We GXTXX promising data share these are excited at ESMO. to
believe the very GXTXX development, of in AE high degree profile early still with for class, seeing are that validation we the with we coupled favorable that is encouraging. the target While
milo The the to endocentric cancer, small cell in by preservation cell chemo trial trials showed two non-small lung improvements cancer. meaningful on addition Last data, will measures. provide across in GXTXX plus lerociclib/Faslodex we for trial, data In update chemo and the trilociclib been trial ESMO other data which and on at Phase accepted detailed centric abstracts have ESMO. presented milo year, X-XA trilociclib lung multiple tumor the being The an results presented efficacy. to milo preservation preservation
efficacy immune in early too As to first not this we've not is cancer trial. tumor is lerociclib/Faslodex sensitive a see have on small-cell lung we do improvement safety the in the It meaningful dose-escalation will portion data. several cohorts the and tolerability any from focus from of the particularly small efficacy in tumor, and significant previously, to a Data noted trial. expect trial
likely like alone. profile. safety and compared and the San I'd was believe make regimen We that immunity. showed is with overall Cancer arrest arms, which due data, is of the clinically Finally, GX about to enhancement of which in we expected trilociclib chemotherapy anti-tumor Breast and the gemcitabine of showed survival data trial this trilociclib announced overall of and next arm. at preformed and in survival arms encouraging following preliminary cut carboplatin data, trilociclib TNBC from as patient to lymphocytes the compared trends recently a with progression-free comments the favorable to a action, and a survival recent each transient trial arms, few is arm, the announced benefit receiving of in to improvement significant with control that significant survival survival a Antonio. an for data which mechanism and statistically and three consistent of the data XXXX, immune-mediated benefit two cycle meaningful cell San chemotherapy comes trilociclib control T from reviewing This Antonio historical Symposium XXX tolerability overall trilociclib's response data. In statistically The pre-specified women The
promising expected receive alone of the patients to benefit year the meeting trilociclib discussing very While the presenting OS to are later control chemotherapy next seen look detailed magnitude not would did in additional be doses We of to randomized more the data this in this month. medical These drive with the at a arms forward findings. arm, chemo trial. FDA them compared and
financials. call Jen of now turn the I'll review for the over to a Jen?
